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Athough there is a profusion of studies related to strategic alliances and technological capacities which evaluate the issues 
individually, there is a scarcity of studies with empirical evidence relative to the implications of strategic alliances at the 
technological capacity configuration. Drawing on a scrutiny of specialised databases (Galé, Dialog, and Business & 
Industry) covering the 1993-2003 period, this article examines the entry and exit composition of innovative capabilities of 
25 pharmaceutical companies’ capabilities involved in such alliances. They are organised in three groups: (i) large 
pharmaceutical companies (‘big-pharma’); (ii) large bio-pharmaceutical companies (‘bio-pharma’); and (iii) small and 
research-intensive companies. In terms of strategic alliance implications, a change was observed on the technological 
capacities’ configuration. The evidence suggests that the criteria for partner choice and technological capacity depend on 
the objectives and needs of each different group of company. Such type of evidence is important to provide researchers, 
corporate managers, and policy-makers with a concrete notion of the extent to which such division of innovative labour 
occurs and the actual changes going on the structure and organisation of innovative activities in the pharmaceutical 
industry.  
 




Over the past three decades the pharmaceutical industry has 
passed through profound changes. Such changes have led to 
a transformation of its knowledge basis, know-how, and 
new search procedures leading to changes in the 
organisation and distribution of innovative activities. 
Among the different business models adopted by the 
pharmaceutical industry along the decades, Fully Integrated 
Pharmaceutical Company (FIPCO) was the business model 
which has provided the big-sized companies a considerable 
growth and high revenues for a long period of time. Based 
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on the integrated activities, this model oriented the 
companies to focus on their own internal resources to 
perform their R&D. But the specificity of the technology 
involved in drug research and the time demanded required 
some adjustments on the integrated model by the big-sized 
pharmaceutical companies. James (2003) draws our 
attention to the necessity of the companies to complement 
their resources with external technological capacities. This 
complementation would be crucial for the competitiveness 
in the multinational pharmaceutical market. Besides this, 
the development of molecule research tools has caused a 
huge impact on the knowledge bases and on the course of 
pharmaceutical company (Leonard-Barton, 1995). 
Specialized technologies like combinatorial chemistry, 
analogue chemical compounds analysis made the search 
process more “guided” and path dependent (see 
Gambardela, 1995; Orsenigo et. al., 2001). 
 
While some would argue that such changes are the result 
the molecular biology ‘revolution’ (Arora & Gambardella, 
1994; Gambardella, 1995), others argue that change 
transition is a consequence of cumulative ‘incremental’ 
changes taking place within pharmaceutical industry (see 
Nightingale & Mahdi, 2004). Such cumulative incremental 
changes seem to have been drive by the gradual and steady 
emergence and development of competitive technologies 
and biological sciences, industrial molecular and cells 
biology, and in biochemistry protein search techniques, 
which, in turn, demand new kinds of highly specialised 
knowledge bases (Pavitt, 1990; Leonard-Barton, 1995).  
 
Nevertheless, there is a consensus that such institutional 
and technical changes have led to fundamental 
modifications to structure of the pharmaceutical industry. 
These have involved, for instance, the emergence of biotech 
start-ups. In other words, such changes have triggered a 
new division of innovative labour between ‘big-pharma’ 
and dedicated biotech firms (specialised suppliers and small 
research-based firms): while small-sized biotech 
concentrate on upstream research the ‘big-pharma’ seeks to 
acquire from them initial drug compounds, to carry out 
costly clinical trials and commercialise such drugs 
worldwide (see Gambardella, 1995; Mazzucato & Dosi, 
2006; Nightingale & Mahdi, 2004). Such ‘division of 
innovative labour’ implies, on the other hand, several kinds 
of knowledge complementarities (Pavitt, 1990) which, in 
turn, are operationalised on the basis of different 
management mechanisms, namely, strategic alliances 
(Forest & Martin, 1992; Rothaermel & Deeds, 2004).  
 
Indeed, over the past decade there have been robust and 
respected studies and analyses of the evolution of the 
pharmaceutical industry, from a capability-based 
perspective. However, there seems to be a scarcity of an 
empirical evidence relative to the implications of such 
‘division of innovative labour’ in the pharmaceutical 
industry, especially based on strategic alliances, for the 
technological capabilities of companies involved in such 
arrangements. Such type of evidence is important to 
provide researchers, corporate managers, and policy-makers 
with a concrete notion of the extent to which such division 
of innovative occurs and the actual changes going on the 
structure and organisation of innovative activities in the 
pharmaceutical industry. 
 
Thus this seeks to make a contribution in that direction.  
Drawing on systematic scrutiny of specialised databases 
such as Galé, Dialog, and Business & Industry covering the 
1993-2003 period, this article examines the implications of 
strategic alliances for the configuration of companies’ 
capabilities that participate in such alliances. Such search 
process was based on evidence of strategic alliances in a 
sample of 25 pharmaceutical companies. In this study, such 
sampled companies have been organised three different 
groups: (i) large pharmaceutical companies (‘big-pharma’); 
(ii) large bio-pharmaceutical companies (‘bio-pharma’); 
and (iii) small and research-intensive companies. 
 
Following this introductory and background section, 
Section 2 presents the framework in the light of which our 
empirical evidence is examined. Issues related to the 
methods of study underpinning this paper are outlined in 
Section 3. The main findings are presented and discussed in 
Section 4. Finally, Section 5 discusses the paper 
conclusions and some recommendations. 
 
2. Descriptive framework   
 
Strategic alliances have been viewed as one of the major 
mechanisms to operationalise the knowledge 
complementarity and division of innovative labour in the 
contemporary pharmaceutical industry (Forrest & Martin, 
1992). In order to sustain innovative and economic 
performance, the pharmaceutical industry needs to launch 
new drugs constantly. The process of obtaining new drugs 
depends, firstly, on the technological capabilities for the 
molecule research and drug development (P&D). The 
necessary investment for a new drug ranges between USD 
800 million and USD 1 billion. Basically, the new drug 
discovery process involves molecule trials, preclinical and 
clinical trials in humans, as well drug development. 
Because clinical trials require high investments, many of 
the strategic alliances take place during these stages. 
Considering only the ten biggest studied “big-pharmas”, the 
total annual revenue was USD 203 billion in 2003 (Tyebiee 
& Hardin, 2004).  
 
Pharmaceutical companies complement their innovative 
resources in order to compete globally (James, 2003). 
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Indeed, Forrest & Martin (1992) found different reasons 
from large pharmaceutical companies and small research-
intensive companies to look for strategic alliances: while 
the former seeks to update their knowledge bases and R&D 
structures in order to keep up their technological and  
leadership in the market with innovative drugs, the latter 
seek to take advantage of their innovative knowledge basis 
in order to capitalise themselves, to share the risks of their 
new investigations and to gain access to markets.  
 
It should be noted that biotechnological companies have 
been responsible for the majority of strategic alliances. 
Between 1988 and 2002, 20,000 strategic alliances were 
registered involving biotechnological companies in the US 
representing. The exploration regime prevails on the 
biotechnological companies when compared with the 
collaboration regime between the companies (Koza & 
Lewin, 1988; Rothaermel & Deeds, 2004). Additionally, 
another reason for the establishment of strategic alliances is 
related to the fact that certain innovative capabilities can be 
under patent protection and under high difficulty of 
replication in the pharmaceutical field (Kotabe & Swan, 
1995; Powell, 1996; Iyer, 2002; Rotharmel & Deeds, 2004). 
  
As a result, Figure 1 presents the descriptive framework in 
the light of which the evidence on strategic alliances based 
on innovative capabilities in the pharmaceutical industry 
will be examined in the article. The framework involves 
three steps: 
 
A  Factors influencing the establishment of strategic 
alliances; 
B  Supply of innovative capabilities and other resources 
to enter to strategic alliances; 
C  Acquisition of innovative capabilities through 
different types of strategic alliances. 
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Figure 1. The study descriptive framework 
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The changing scenario is represented by numbers 1, 2 and 3 
in Figure 1: (1) need of commercial use of innovative 
capabilities, (2) limitations of the existing FIPCO business 
model, (3) need of financial support.  Drawing on Pavitt 
(1990), Leonard-Barton (1995), Teece & Pisano (1994) and 
Tidd et al. (2001), this model is based on the concept that 
the companies gain and sustain their competitive advantage 
on the basis of their innovative capabilities and cognitive 
bases.  
 
The three types of companies which participated on the 
studied strategic alliances are represented by Number 5 in 
Figure 1: ‘big-pharma’, ‘bio-pharma’ and small & reseach –
intensive company. In this study, we adopt a broad 
perspective on technological capabilities involving in 
strategic alliances in the pharmaceutical industry: techno-
organizational system (TOS), molecule and drug.  
 
These three different capability resources are identified by 
Number 6 and are part of the technological capabilities 
which were used to enter to strategic alliances. The 
different kinds of collaborations among the three types of 
company and strategic alliance mechanisms are represented 
by Number 7. Number 8 refers to the technological 
capabilities that result from strategic alliances established 
by each type of pharmaceutical company (exit capabilities) 
 
3. Study design and methods 
3.1 Central question 
 
The study underlying this paper has been structured to 
evaluate the following central issues: (i) the technological 
capacities which were made available at the strategic 
alliances by the three groups of pharmaceutical companies 
(big-pharma, bio-pharma and small-sized research-intensive 
company) and (ii) the main implications of strategic 
alliances for the different groups of company.. The strategic 
alliances studied involved different mechanisms: in/out 
licenses of technological capabilities; creation of techno-
organizational systems; molecule research; drug 
development and marketing & sales development. 
Technological capabilities are understood here as 
knowledge-based resources that are needed to generate and 
manage technological innovation. Such resources are 
embodied in techno-physical systems, people, and 
managerial and organisational systems (Bell & Pavitt, 
1995; Leonard-Barton, 1995; Figueiredo, 2001). Thus, in 
this paper innovative capabilities involve different 
knowledge basis related to new drug development process: 
techno-organisational system (TOS); molecule, and drug. 
The TOS can be a tool for the molecule research equipment 
development; equipment for molecule research and 
equipment for drug development. 
 
3.2 Sampling  
 
We have scrutinised the strategic alliances implemented 
during the 1993-2003 period by three types of companies as 
shown in Table 1 below.  The criterion to select big-
pharmas and bio-pharmas was based on the revenue in 
2003. For the five small & research-intensive companies, 
the criterion was the frequency on strategic alliances agreed 
with big-pharmas. 
 
Table  1. Sample of the study 
Types of companies Companies 
Large multinational pharmaceutical company (‘big 
pharma’): 
Pfizer; Glaxo SmithKline; Merck; Johnson & 
Johnson; Aventis; AstraZeneca; Novartis; Bristo-
Myers Squibb; Roche, and Eli Lilly 
Large multinational bio-pharmaceutical companies 
(‘bio-pharmas’): 
Amgen; Genentech; Serono; Biogen Idec; 
Genzyme; Chiron; MedImmune; Gilead; 
Millennium; and Intermune 
Small and research-intensive rcompanies Incyte; Icagen; Lexicon; Ligand and OSI 
Pharmaceuticals. 
 
Our search of empirical evidence drew on three large 
databases: Business & Industry; Dialog and Galé. The 
homepages of each studied company and the specialized 
publications (e.g.: IMS, Pharma) were also examined. The 
survey of the empirical evidences considered the 
publications between 1993 and 2003. The used terms for 
the strategic alliances survey are related to: strategic 
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Table 2. Terms used for searching the selected databases 
 
Search (S1): alliance or agreement or licenses or partnership or collaborative development 
Search (S2): molecule discovery or drug discovery or early discovery 
Search (S3): name of the company** 
Search (S4): S1 and S2 and S3 and PY = 1993:2003 
** the names of the 25 companies (sample). 
 
In order to simplify the assessment of the collected data, 
each technological capability (which was made available at 
the strategic alliance or which was acquired through 
strategic alliance) was considered as one strategic alliance. 
All qualitative information related to each strategic alliance 
was represented as one technological capability at the table 
of the corresponding company. The frequency of each 
technological capability generated a quantitative data. Such 
data were organized in tables and graphics in order for us to 
obtain a meaningful evaluation and discussion of evidence. 
Mergers, take-overs and joint-ventures were outside the 




4. Main results and discussions 
In this section we present the main results obtained from 
our empirical search. The results are presented in three 
Subsections in order to provide a better understanding of 
how different groups of company participated with their 
resources, as well how different interests generated a 
modification between the configuration of technological 
capabilities which were made available at the strategic 
alliances and the configuration of technological capabilities 
which were captured through the same strategic alliances. 
 
4.1. Participation of companies’ capabilities in the 
establishment of strategic alliances 
Figures 2 to 4 illustrate the participation of each type of 
company with technological capabilities. 
 
Figure 2.  Innovative capabilities to enter strategic alliances: big pharmas 
‘C’ vs partners  ‘P’ 
 
 
Notes/keys: C = innovative capabilities which were made available by the big pharma group;  
P = innovative capabilities which were made available by partners (biopharma, big pharma and small and research-
intensive company involved on the studied strategic alliances);  




Figure 2 indicates a small participation of big-pharmas in 
examined strategic alliances in terms of innovative 
capabilities. From all strategic alliances agreed between 
big-pharmas and the correspondent partner, only 19 out of 
169 capacities (11%) came from big-pharmas. The more 
relevant participation from this group was with drugs 
(30%). 
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Figure 3. Innovative capabilities to enter strategic alliances:  
bio-pharmas ‘C’ vs partners ‘P’ 
 
Notes/keys: C = innovative capabilities which were made available by the biopharma group;  
P = innovative capabilities which were made available by partners (bio-pharma, big pharma and small research-intensive 
companies involved in the strategic alliances);  
B = innovative capabilities which were made available by both companies (bio-pharma and the partner involved on the 
strategic alliance). 
 
On the other hand, Figure 3 shows a balanced participation 
of bio-pharmas in terms of technological capabilities in the 
strategic alliances. They contributed with 63 out of 143 
capacities (44%). This group participated with more than 
70% of the drugs and, numerically, on TOS for molecule 




Figure 4. Innovative capabilities to enter strategic alliances: 
small and research-intensive ‘C’ vs partners ‘P’ 
 
 
Note/keys: C = innovative capabilities which were made available by the small-sized intensive research company group;  
P = technological capabilities which were made available by partners (biopharma, big pharma and small and research-
intensive companies involved on the studied strategic alliances);  
B = innovative capabilities which were made available by both companies (small and research-intensive companies and the 
partner involved on the strategic alliance). 
 
The evidence in Figure 4 indicates a strong participation of 
small & research intensive companies in the strategic 
alliances with technological capabilities: 68 out of 95 
capacities (72%). Within the examined strategic alliances 
they had impressive participation both in proportional terms 
(83% with TOS for TOS creation and 69% for TOS for 
molecule research) and absolute terms: 49 out of 71 TOS 
for molecule research. 
The above empirical evidence suggests that there was a 
higher participation of small & intensive research 
companies in the strategic alliances in terms of innovative 
technological capabilities. Big-pharmas contributed mainly 
with financial support and marketing & sales structure. Bio-
pharmas participated with technological capabilities and 
financial support, depending on the involved partner. 
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Indeed, big-pharmas adopted the strategic alliances as a 
way of acquiring new technological capabilities as a 
response to their internal limitations such as low 
productivity of their internal R&D structures, reduction of 
the profit from new drug’s launch and external limitations 
like, on the one hand, the increased scientific sophistication 
of products and, on the other, the enlargement of the market 
for generic products (James, 2003). In relation to bio-
pharmas, their engagement in strategic alliances was driven 
by the need to complemented technological capabilities in 
order to improve their financial structure and to obtain 
innovative drugs. Small and research-intensive companies 
adopted the strategic alliances for commercial application 
of their in-house innovative technological capabilities and 
to engage in new activities such as drug commercialization 
in the global pharmaceutical market, thus, in line with 
Forrest (1990).  
 4.2 Composition of innovative capabilities used by 
companies to enter strategic alliances 
Figures 5 to 7 show the composition of innovative 
capabilities that made available by the three types of 
companies during the establishment of the examined 
strategic alliances. 
 
Of the 19 technological capabilities which were made 
available by big-pharmas, the great majority of them 
referred to drugs (47%). The empirical evidence suggests 
that the majority of these drugs were on the verge of losing 
their patent protection or having already lost it. Big-
pharmas also participated considerably with techno-
organizational system for molecule research (see Figure 5) 
 




Of the 63 technological capabilities which were made 
available by bio-pharmas at the studied strategic alliances, 
it was observed that great part was techno-organizational 
system (TOS) for molecule research (49%). The empirical 
evidence indicates that most part of these TOS was made 
available to big-pharmas. This, in turn, suggests that  bio-
pharmas participated considerably with molecules and 
drugs (see Figure 6). 
 
 




Of the 68 technological capabilities which were made 
available by the small & research-intensive companies, it 
was observed that the great majority of them being based 
on TOS for molecule research (93%). The great part of 
these TOS was made available to big-pharmas. 
Additionally, we can observe a contribution with TOS for 
molecule research (see Figure 7). 
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The evidence in Figures5 to 7 allows us to observe an 
unbalanced composition of  capabilities offered by big-
pharmas in contrast to small & research-intensive 
companies to enter to their strategic alliances. While the 
participation of the former was mainly with drugs (47%), 
the latter contributed heavily with TOS (93%). Besides the 
fact that the participation of bio-pharmas was much more 
balanced, this company profile presented a considerable 
contribution with TOS (50%). 
 
4.3 Composition of innovative capabilities resulted 
from strategic alliances 
Figures 8 to 10 illustrate the composition of the 
technological capabilities during the exit of companies from 
the examined strategic alliances. 
 
 
Figure 8. Big-pharmas’ innovative capabilities exiting from strategic alliances 
 
 
Of the 206 technological capabilities resulting from the big-
pharmas studied strategic alliances, 143 (69%) were 
retained by big-pharmas (55% of them were related to 
molecules). This type of company also acquired a 
considerable number of TOS for molecule research, 
reinforcing the idea that the main interest of this type of 
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Of the 170 technological capabilities resulting from the bio-
pharmas studied strategic alliances, 59 (35%) were retained 
by the bio-pharmas (55% were TOS for molecule research). 
According to the empirical evidence, the majority of these 
TOS for molecule research resulted from in-licensing with 
small & research-intensive companies and other bio-
pharmas. Bio-pharmas also acquired a considerable number 
of molecules (32%) through in-licensing and molecule 
research mechanisms. This, again, confirm their interest in 
molecules. 
 
Figure 10. Small & research-intensive firms’ innovative capabilities 





Of the 109 technological capabilities resulted from the 
studied strategic alliances, only 17 (16%) of them were 
retained by small & research-intensive companies. It was 
observed that the majority of them were based on TOS for 
molecule research (71%). This type of company also 
acquired a considerable number of drugs, which, in turn, 
seems to suggest their interest in gaining share in the 
pharmaceutical market. 
 
In sum, we have found that: 
 
(1) In terms of contribution with technological 
capabilities to strategic alliances: (i) big-pharmas 
participated with 11% of 169 technological 
capabilities; (ii) bio-phamas participated with 44% 
of 143 technological capabilities; (iii) small-sized 
intensive research companies participated with 
72% of 95 technological capabilities. 
 
(2) In terms of the composition of  technological 
capabilities obtained from strategic alliances when 
compared with the configuration of the 
technological capabilities which were made 
available for the strategic alliances: (i) big-
pharmas increased the proportion of molecules 
(16% to 55%); (ii) bio-pharmas increased the 
participation in molecules (22% to 32%) and 
techno-organizational system to molecule research 
(49% to 55%); (iii) small & research-intensive 
companies started new activity: drug 
commercialization on pharmaceutical market with 
a corresponding increase of drugs (3% to 29%). 
Furthermore, this type also company updated its 
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techno-organizational system (TOS) for molecule 
research. 
 
Finally, Table 3 shows the percentage of each technological 
capability which was made available during the start of the 
studied strategic alliances by each kind of company. It also 
shows the percentage of each technological capability 
which was obtained by each of the three types of companies 
from the same strategic alliances.  
 
 
Table 3. Entry and exit innovative capabilities of pharmaceutical companies  
involved in strategic alliances 
 
Types of innovative  
capability 
Big Pharmas Biopharmas Small & research- 
companies 






























Molecules 16 % 55% 22 % 32% 3 % None 
TOS for molecule research 32 % 23% 49 % 55% 72 % 71% 
 
TOS for TOS creation 









22 % No 
capability 
addition 
Total 100% 100% 100% 100% 100% 100% 
Note: (* ) Innovative capabilities that were made available at strategic alliances 
         (**) Innovative capabilities that were obtained from the strategic alliances 
 
 
The evidence in Table 3 allows us to observe some 
modifications in the compositions of the technological 
capabilities of the companies involved in the examined 
strategic alliances.  In general, big-pharmas participated in 
strategic alliances in order to obtain innovative capabilities; 
bio-pharmas sought to complement their capabilities, while 
small & research-intensive companies were interested in 
starting new activities and entering the pharmaceutical 
market. 
 
5. Conclusions  
 
Although there have been a number of studies on strategic 
alliances and technological capabilities and those that point 
to division of innovative labour in the pharmaceutical 
industry, our study have sought to add, although in a very 
descriptive manner, a concrete notion of the extent to which 
pharmaceutical companies benefit from their strategic 
alliances in terms of technological capabilities.  
 
Based on the empirical evidences, it was observed that the 
participation of the three groups at the strategic alliances 
was influenced by the availability of technological capacity: 
big-pharmas participated mainly with financial support; the 
small-sized intensive research companies with their 
technological capacities and the bio-pharmas with their 
technological capacities and financial support, depending 
on the partners. 
 
According to the technological capacities resulting from the 
strategic alliances, it can be inferred that big-pharmas 
detained molecules to guarantee the market 
competitiveness; bio-pharmas detained molecules to 
improve the financial structure as well as TOS for molecule 
research to maintain their P&D activities; and the small-
sized research companies acquired drugs to enter the 
pharmaceutical market. 
 
Taking into consideration that big pharmas have held the 
largest amount of technological capacities from the 
strategic alliances, in particular molecules, it can be 
understood that their interest in participating in strategic 
alliances should be a way of reacting at internal and 
external changes, with the objective of keeping 
competitiveness in the pharmaceutical market. This reaction 
has modified the main business model (FIPCO) followed 
by this company profile. This business model, which is 
integrated and self-sufficient, now starts to accept external 
technological capacities that have led to the reduction of the 
resource waste. 
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With innovative molecules and acting in an intensive way 
on P&D, the efficient and profitable bio-pharmas have been 
adopting strategic alliances in order to complement their 
technological capacities, as well as outsourcing the 
biotechnological products manufacturing. It was observed 
that this group participated in a diversified way at the 
strategic alliances with technological capacities; financial 
support; targeting molecules and technical-operation 
systems. It. seems that all these efforts are being made to 
reach revenues higher than those of the big-pharmas. 
 
On their turn, small-sized intensive research companies can 
take advantage of their innovative capabilities to enter the 
pharmaceutical market through the commercialization of 
the drugs acquired by strategic alliances. Due to the fragile 
financial structure, this group is more affected by the 
election of the partnership. The partner has to optimize their 
technological capacities and to reinforce their technological 
bases (Meyer apud Forrest, 1990). 
 
The strategic advantage demands more and more 
integration of the external technological capacities. Some 
positive conclusions for strategic alliance can be 
considered, like the sharing of responsibilities, the 
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